John Davis Ph.D, Scientific Advisor
John Davis is Chief Scientific Officer of the Alzheimer’s Research UK Oxford Drug Discovery Institute. He has over 20 years’ drug discovery experience from SmithKline Beecham, GlaxoSmithKline, Convergence Pharmaceuticals and Selcia. He was a research fellow at the Ludwig Institute for Cancer Research and Salk Institute for 6 years before joining SmithKline Beecham (later GlaxoSmithKline) in 1993. His roles at GSK included director of neurodegeneration research and director of biology for pain and epilepsy research; he was also instrumental in the formation and management of several large collaborations with universities. He was a co-founder of Convergence Pharmaceuticals where he served as Head of Biology from 2010-2013, and then joined Selcia as Director of Discovery. He originally trained as a biochemist, has a PhD from Cambridge University and is the author of over 100 peer reviewed publications and patents.
Professor Robert Sutton, Scientific Advisor
Robert Sutton is Professor of Surgery, Institute of Translational Medicine, University of Liverpool, Director of NIHR Pancreas BRU, NIHR Senior Investigator & an acknowledged world expert in treatment of acute pancreatitis. Professor Sutton is highly engaged with industry and the infrastructure at Liverpool provides access to the MHRA accredited Phase I clinical research unit at The Royal Liverpool University Hospital.
Gavin Kilpatrick Ph.D., Scientific Advisor
Gavin Kilpatrick has over 30 years of experience of drug discovery and development in the biotechnology and pharmaceutical sectors. He has held senior management positions at GSK, CeNeS, Roche and Takeda. Gavin was founder and CSO of the biotechnology company TheraSci Ltd and, as CSO, a board member of the listed German biopharmaceutical company, PAION AG. Gavin holds a PhD in pharmacology from the London Institute of Psychiatry (part of King's College), is a Fellow of the British Pharmacological Society and has authored more than 80 peer-reviewed publications and patents.
Paul Rees Ph.D., Scientific Advisor
Paul has 25 years experience in Clinical Research and Global Medicines Development at GSK and its heritage companies. He has particular expertise in the leadership of global development projects in critical care, inflammatory disease, neurodegeneration and rare diseases including a number of successful NDA/MAA’s and launches. He is currently an advisor and consultant on medicines development to companies in the biotechnology arena. Paul holds a PhD in Clinical Pharmacology from the University of Southampton and is a Visiting Senior Lecturer in Pharmaceutical Medicine at Kings College London (KCL).
Please contact us to explore opportunities for collaboration or investment.